The short answer
GLP-1 receptor agonists slow gastric emptying, so a patient who has fasted normally before a procedure may still have residual stomach contents. That raises the risk of aspiration under anaesthesia, and gastric ultrasound studies have been used to measure it directly.
Key facts
- Mechanism
- Delayed gastric emptying
- Consequence
- Residual gastric content despite fasting
- Risk
- Pulmonary aspiration under anaesthesia
- Assessment tool
- Gastric ultrasound
- Key study
- JAMA Surgery 2024 (PMID 38446466)
- Follow-up
- Anesth Analg 2026 (PMID 41032460)
- Nature of risk
- Mechanism-linked, not idiosyncratic
Why fasting rules exist
Anaesthesia suppresses the airway reflexes that normally prevent stomach contents entering the lungs. Pre-operative fasting periods exist so the stomach is empty by the time those reflexes are lost. The rules assume a normal gastric emptying rate (a few hours for a light meal), and that assumption is what a GLP-1 agonist breaks.
How the drug changes the arithmetic
Delayed gastric emptying is not a side effect of these compounds in the incidental sense. It is part of how they work: slowing the delivery of nutrients into the small intestine blunts the post-meal glucose rise and prolongs the sensation of fullness. A drug deliberately slowing that process will leave contents in the stomach longer than the fasting guidance assumes, and the same mechanism producing the therapeutic effect produces the perioperative problem.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the studies measured
Sen and colleagues reported in JAMA Surgery in June 2024 on residual gastric content before procedures in patients using GLP-1 receptor agonists. Pai and colleagues followed in Anesthesia & Analgesia in April 2026 with an assessment using gastric ultrasound. Ultrasound is the right tool here because it visualises stomach contents directly at the point of care, rather than inferring emptying from an indirect marker.
Why this became a practical issue rather than a theoretical one
Scale. When a small number of patients took these drugs the interaction with elective surgery was a footnote. With very large populations on them, and in the UK a substantial share obtaining them privately, anaesthetists began encountering unexpectedly full stomachs in properly fasted patients often enough to change practice. Professional societies have issued guidance, and pre-operative questioning about GLP-1 use has become routine.
The private-prescription complication
This connects directly to the point the MHRA made in its February 2026 NAION update: privately prescribed semaglutide may not appear on a medical record. An anaesthetist reading a drug history may not see it. That is why the practical guidance is to ask the patient directly rather than rely on the record. The same structural gap produces the same recommendation in two unrelated safety contexts.
What this is and is not
It is a well-characterised, mechanism-linked interaction between a drug class and a procedure, managed through pre-operative assessment. It is a clinical matter for prescribers and anaesthetists. Nothing here is guidance for anyone, and material supplied for laboratory research is not related to it. The underlying pharmacology, though, that delayed gastric emptying is inseparable from GLP-1 receptor agonism, is the same principle described throughout this category.
Frequently asked questions
Why does a GLP-1 drug affect anaesthesia?
It slows gastric emptying, so a patient who has fasted according to standard guidance may still have stomach contents, raising aspiration risk when airway reflexes are suppressed.
Is this a rare idiosyncratic reaction?
No. It follows directly from the drug's mechanism: delayed gastric emptying is part of how these compounds work, not an unrelated side effect.
How is residual gastric content assessed?
Gastric ultrasound visualises stomach contents directly at the point of care, which is why it features in the published studies.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSen S et al., GLP-1 receptor agonist use and residual gastric content. JAMA Surg 2024 (PMID 38446466)pubmed.ncbi.nlm.nih.gov
- PubMedPai SL et al., Gastric ultrasound in patients on GLP-1 receptor agonists. Anesth Analg 2026 (PMID 41032460)pubmed.ncbi.nlm.nih.gov
- PubMedKunutsor SK et al., Safety and tolerability of GLP-1 receptor agonists. Drugs 2026 (PMID 41351656)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- GLP-1 Gastrointestinal Safety SignalsGastroparesis, pancreatitis and bowel obstruction have all been raised as GLP-1 signals. What the comparative cohort data shows, and how the compounds differ.
- How to Read a Pharmacovigilance SignalA reporting odds ratio of 19 does not mean a nineteen-fold risk. What FAERS disproportionality measures actually mean, and why they are so often misreported.
- Danuglipron: The Oral GLP-1 Pfizer StoppedPfizer halted danuglipron in April 2025 after one asymptomatic liver injury case. Why a single event ended a programme that had met its objectives.
- Why Hepatic Safety Became the Oral GLP-1 QuestionInjectable peptide GLP-1s did not raise this question. Small molecules do, because of how they are metabolised - and one programme has already ended over it.
- Hy's Law: How Trials Decide a Drug Hurt the LiverThree measurements and an exclusion. What Hy's Law is, why it predicts severe outcomes, and why raised enzymes alone mean very little.